Back to Trades
Other4
Astria Therapeutics, Inc.
ATXS
Total Value
$1.8M
Company Information
- Company Name
- Astria Therapeutics, Inc.
- Ticker Symbol
- ATXS
- CIK
- 0001454789
Insider Information
- Name
- Komjathy Andrew
- Role
- Insider
- Location
- BOSTON, MA
Filing Details
- Filing Date
- Jan 23, 2026
- Transaction Date
- Jan 23, 2026
- Accession Number
- 0000905148-26-000319
- Form Type
- 4
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jan 23, 2026 | Common Stock | 10 | — | Disposition | — |
| Jan 23, 2026 | Common Stock | 45 | — | Disposition | — |
| Jan 23, 2026 | Common Stock | 45 | — | Disposition | — |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jan 23, 2026 | Derivative | 55,000 | $6.51 | Disposition | $358.1K |
| Jan 23, 2026 | Derivative | 225,000 | $6.41 | Disposition | $1.4M |
Footnotes
- (F1)Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of Issuer common stock, excluding shares held by the Issuer, BioCryst, or their wholly-owned subsidiaries or dissenting stockholders, that was issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.59 of a share of common stock of BioCryst and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest, subject to withholding taxes.
- (F2)These shares are held in a Uniform Transfers to Minors Act brokerage account of the Reporting Person's minor child (the "UTMA"), of which the Reporting Person serves as the sole custodian trustee. The Reporting Person disclaims beneficial ownership over these shares of common stock, which are held directly by the UTMA, except to the extent of the Reporting Person's indirect pecuniary interest therein.
- (F3)These shares are held by the Reporting Person's adult child. The Reporting Person disclaims beneficial ownership over these shares of common stock, which are held directly by the adult child of the Reporting Person.
- (F4)At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.